Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,736

The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death

Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,909

The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene

Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789

Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6

Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440

SRα Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat

Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., & Arai, N. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.1.466-472.1988 · Cited by 1,330

A novel domain within the 55 kd TNF receptor signals cell death

Tartaglia, L. A., Ayres, T. M., Wong, G. H., & Goeddel, D. V. (1993) · Cell · doi:10.1016/0092-8674(93)90464-2 · Cited by 1,290

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,108

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004

OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION

Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934

Proposed Standard Nomenclature for New Tumor Necrosis Factor Family Members Involved in the Regulation of Bone Resorption

(2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.12.2293 · Cited by 64

Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis

Sasaki, N., Kusano, E., Ando, Y., Nemoto, J., Iimura, O., Ito, C., Takeda, S., Yano, K., Tsuda, E., & Asano, Y. (2002) · Bone · doi:10.1016/s8756-3282(02)00742-1 · Cited by 63

Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers

Uemura, H., Yasui, T., Kiyokawa, M., Kuwahara, A., Ikawa, H., Matsuzaki, T., Maegawa, M., Furumoto, H., & Irahara, M. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740353 · Cited by 63

What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?

de Vries, T. J., el Bakkali, I., Kamradt, T., Schett, G. A., Jansen, I. D. C., & D’Amelio, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00505 · Cited by 63

Prolactin: A hormone with diverse functions from mammary gland development to cancer metastasis

Atıcı, Ö. K., Govindrajan, N., Lopetegui-Gonzalez, I., & Shemanko, C. S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.10.005 · Cited by 63

Activation of peroxisome proliferator-activated receptor inhibits osteoprotegerin gene expression in human aortic smooth muscle cells

Fu, M., Zhang, J., Lin, Y. G., Zhu, X., Willson, T. M., & Chen, Y. E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00533-8 · Cited by 63

Regulation of Osteoclast Formation and Function*

Duong, L. T., & Rodan, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010063225902 · Cited by 62

Commitment and differentiation of stem cells to the osteoclast lineage

Hayashi, S.-I., Yamane, T., Miyamoto, A., Hemmi, H., Tagaya, H., Tanio, Y., Kanda, H., Yamazaki, H., & Kunisada, T. (1998) · Biochemistry and Cell Biology · doi:10.1139/o98-099 · Cited by 63

Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62

Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity

Kimura, S., Nakamura, Y., Kobayashi, N., Shiroguchi, K., Kawakami, E., Mutoh, M., Takahashi‐Iwanaga, H., Yamada, T., Hisamoto, M., Nakamura, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13883-y · Cited by 61

Benefits and mechanisms of polysaccharides from Chinese medicinal herbs for anti-osteoporosis therapy: A review

Lei, S. S., Su, J., Zhang, Y., Huang, X. W., Wang, X. P., Huang, M. C., Li, B., & Shou, D. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.030 · Cited by 62

A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats

Li, Y.-J., Kukita, A., Teramachi, J., Nagata, K., Wu, Z., Akamine, A., & Kukita, T. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.111 · Cited by 62

Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside—a Comprehensive Review

Alves, C. H., Farrell, E., Vis, M., Colin, E. M., & Lubberts, E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8522-7 · Cited by 65

Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw

Manzano‐Moreno, F. J., Ramos‐Torrecillas, J., Melguizo‐Rodríguez, L., Montes, R. I., Ruíz, C., & García‐Martínez, O. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.22627 · Cited by 67

Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-κB and receptor activator of nuclear factor κB (RANK)/RANK ligand signaling?

van Bezooijen, R. L., Papapoulos, S. E., & Löwik, C. W. G. M. (2001) · Bone · doi:10.1016/s8756-3282(00)00457-9 · Cited by 62

Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin

Shiotani, A., Takami, M., Itoh, K., Shibasaki, Y., & Sasaki, T. (2002) · The Anatomical Record · doi:10.1002/ar.10121 · Cited by 63

Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss

Titanji, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01851 · Cited by 61

Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer’s disease

Luckhaus, C., Mahabadi, B., Grass‐Kapanke, B., Jänner, M., Willenberg, H. S., Jäger, M., Supprian, T., & Fehsel, K. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0241-x · Cited by 61

RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases

Yasuda, H. (2013) · World Journal of Orthopedics · doi:10.5312/wjo.v4.i4.207 · Cited by 62

Regulatory Effects of Interleukin‐1β and Prostaglandin E2 on Expression of Receptor Activator of Nuclear Factor‐κB Ligand in Human Periodontal Ligament Cells

Nukaga, J., Kobayashi, M., Shinki, T., Song, H., Takada, T., Takiguchi, T., Kamijo, R., & Hasegawa, K. (2004) · Journal of Periodontology · doi:10.1902/jop.2004.75.2.249 · Cited by 61

Osteoprotegerin levels before and after renal transplantation

Sato, T., Tominaga, Y., Iwasaki, Y., Kazama, J. J., Shigematsu, T., Inagaki, H., Watanabe, I., Katayama, A., Haba, T., Uchida, K., et al. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27437 · Cited by 61

Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures

Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60

Bone remodelling in inflammatory arthritis

Goldring, S. R., Purdue, P. E., Crotti, T. N., Shen, Z., Flannery, M. R., Binder, N. B., Ross, F. P., & McHugh, K. P. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202199 · Cited by 61

Role of the RANK/RANKL pathway in breast cancer

Kiesel, L., & Kohl, A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.001 · Cited by 64

Cytokines, Osteoprotegerin, and RANKL In Vitro and Histomorphometric Indices of Bone Turnover in Patients With Different Bone Diseases

Siggelkow, H., Eidner, T., Lehmann, G., Viereck, V., Raddatz, D., Munzel, U., Hein, G. E., & Hüfner, M. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.529 · Cited by 59

Molecular and Cellular Mechanisms of Mammalian Cell Fusion

Zhou, X., & Platt, J. L. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-0763-4_4 · Cited by 60

RANK as a therapeutic target in cancer

González‐Suárez, E., & Sanz‐Moreno, A. (2016) · FEBS Journal · doi:10.1111/febs.13645 · Cited by 59

Immune mediators in the tumor microenvironment of prostate cancer

Dai, J., Lü, Y., Roca, H., Keller, J. M., Zhang, J., McCauley, L. K., & Keller, E. T. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0198-3 · Cited by 60

Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin

Velletri, T., Huang, Y., Wang, Y., Li, Q., Hu, M., Xie, N., Yang, Q., Chen, Q., Chen, Q., Shou, P., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0590-4 · Cited by 60

Immunohistochemical expression of RANK, GRα and CTR in central giant cell granuloma of the jaws

Tobón‐Arroyave, S. I., Franco-González, L. M., Isaza‐Guzmán, D. M., Flórez‐Moreno, G. A., BRAVOVASQUEZ, T., CASTANEDAPELAEZ, D., & Vieco‐Durán, B. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2004.11.006 · Cited by 59

CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption

Heinrich, J., Bsoul, S., Barnes, J., Woodruff, K., & Abboud, S. L. (2005) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2005.02.007 · Cited by 58

Cytokines and Bone Remodeling

Mundy, G. R., Oyajobi, B. O., Gutierrez, G. E., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50020-3 · Cited by 59

NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K

Lange, A. W., & Yutzey, K. E. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.01.017 · Cited by 59

Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption

Peng, S., Liu, X. S., Zhou, G., Li, Z., Luk, K. D. K., Guo, X.-D. E., & Lu, W. W. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.325 · Cited by 58

Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells

Maddi, A., Hai, H., Ong, S., Sharp, L., Harris, M., & Meghji, S. (2006) · Bone · doi:10.1016/j.bone.2006.01.162 · Cited by 59

Expression of RANKL/OPG during bone remodeling in vivo

Tanaka, H., Mine, T., Ogasa, H., Taguchi, T., & Liang, C. T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.001 · Cited by 59

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease

Bernardi, S., Bossi, F., Toffoli, B., & Fabris, B. (2016) · BioMed Research International · doi:10.1155/2016/1752854 · Cited by 59

Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression

Kim, Y. H., Kim, G.-S., & Baek, J. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.21 · Cited by 58

Coupling of Bone Resorption and Formation during Bone Remodeling

Martin, T. J., & Rodan, G. A. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50013-1 · Cited by 58

Osteoclastic bone resorption induced by innate immune responses

Koide, M., Kinugawa, S., Takahashi, N., & Udagawa, N. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00355.x · Cited by 58

Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men

Yamada, Y. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00125-2 · Cited by 56

Bone Structure, Development and Bone Biology

Safadi, F. F., Barbe, M. F., Abdelmagid, S. M., Rico, M. C., Aswad, R. A., Litvin, J., & Popoff, S. N. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-347-9_1 · Cited by 75

Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells

Suzuki, J., Ikeda, T., Kuroyama, H., Seki, S., Kasai, M., Utsuyama, M., Tatsumi, M., Uematsu, H., & Hirokawa, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.191 · Cited by 61

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 57

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 60

Role of the A20-TRAF6 Axis in Lipopolysaccharide-mediated Osteoclastogenesis

Mabilleau, G., Chappard, D., & Sabokbar, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.150300 · Cited by 57

Enhancement of periodontal tissue regeneration by transplantation of osteoprotegerin-engineered periodontal ligament stem cells

Su, F., Liu, S., Ma, J., Wang, D., Lingling, E., & Liu, H. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0023-3 · Cited by 56

Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D A Pilot Study in Sprague-Dawley Rats

Grases, F., Sanchís, P., Perelló, J., Isern, B., Prieto, R., Fernández-Palomeque, C., & Torres, J. J. (2007) · Circulation Journal · doi:10.1253/circj.71.1152 · Cited by 55

Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma

Lamoureux, F., Picarda, G. G. A., Garrigue‐Antar, L., Baud’huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédiní, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2648 · Cited by 59

Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities

Wittrant, Y., Théoleyre, S., Couillaud, S., Dunstan, C. R., Heymann, D., & Rédiní, F. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.10.016 · Cited by 55

Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D 3 ) Inversely Regulate OPG Gene Expression in Dependence of the Osteoblastic Phenotype

Varga, F., Spitzer, S., & Klaushofer, K. (2004) · Calcified Tissue International · doi:10.1007/s00223-003-0033-5 · Cited by 55

RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in Arthropathies

Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0298-6_7 · Cited by 54

Focal bone involvement in inflammatory arthritis: the role of IL17

Rossini, M., Viapiana, O., Adami, S., Idolazzi, L., Fracassi, E., & Gatti, D. (2015) · Rheumatology International · doi:10.1007/s00296-015-3387-x · Cited by 55

The Roadmap of RANKL/RANK Pathway in Cancer

Casimiro, S., Vilhais, G., Gomes, I., & Costa, L. (2021) · Cells · doi:10.3390/cells10081978 · Cited by 55

Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane

O’Brien, E. A., Williams, J. H. H., & Marshall, M. J. E. (2001) · Bone · doi:10.1016/s8756-3282(00)00431-2 · Cited by 56

Distinct Osteoclast Precursors in the Bone Marrow and Extramedullary Organs Characterized by Responsiveness to Toll-Like Receptor Ligands and TNF-α

Hayashi, S., Yamada, T., Tsuneto, M., Yamane, T., Takahashi, M., Shultz, L. D., & Yamazaki, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5130 · Cited by 55

Wear‐particle–induced osteoclast osteolysis: The role of particulates and mechanical strain

MacQuarrie, R., Chen, Y. F., Coles, C. P., & Anderson, G. I. (2004) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.20031 · Cited by 53

The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion

Joseph, F., Chan, B. Y., Durham, B. H., Ahmad, A. M., Vinjamuri, S., Gallagher, J. A., Vora, J. P., & Fraser, W. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1832 · Cited by 53

High-Dose Diosgenin Reduces Bone Loss in Ovariectomized Rats via Attenuation of the RANKL/OPG Ratio

Zhang, Z., Song, C., Fu, X., Liu, M., Li, Y., Pan, J., Liu, H., Wang, S., Xiang, L., Xiao, G. G., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150917130 · Cited by 56

Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells

Qian, H., Zhao, Y., Peng, Y., Han, C., Li, S., Huo, N., Ding, Y., Duan, Y., Xiong, L., & Sang, H. (2010) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2009.01265.x · Cited by 53

RANK signalling in bone lesions with osteoclast-like giant cells

Won, K. Y., Kalil, R. K., Kim, Y. W., & Park, Y.-K. (2011) · Pathology · doi:10.1097/pat.0b013e3283463536 · Cited by 53

Single Nucleotide Polymorphisms in the Human Gene for Osteoprotegerin are Not Related to Bone Mineral Density or Fracture in Elderly Women

Brändström, H., Gerdhem, P., Stiger, F., Obrant, K. J., Melhus, H., Ljunggren, Ö., Kindmark, A., & Åkesson, K. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2136-9 · Cited by 53

Cell-to-Cell Adhesion via Intercellular Adhesion Molecule-1 and Leukocyte Function-Associated Antigen-1 Pathway Is Involved in 1.ALPHA.,25(OH)2D3, PTH and IL-1.ALPHA.-Induced Osteoclast Differentiation and Bone Resorption.

Okada, Y., Morimoto, I., Ura, K., Watanabe, K., Eto, S., Kumegawa, M., Raisz, L. G., Pilbeam, C. C., & Tanaka, Y. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.483 · Cited by 53

Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?

Wagner, D., & Fahrleitner‐Pammer, A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0818-x · Cited by 53

Osteoimmunology in orthodontic tooth movement

Jiang, C., Li, Z., Quan, H., Li, X., Zhao, J., Jiang, C., Wang, Y., Liu, J., Gou, Y., An, S., et al. (2014) · Oral Diseases · doi:10.1111/odi.12273 · Cited by 54

Bone resorption control of tooth eruption and root morphogenesis: Involvement of the receptor activator of NF‐κB (RANK)

Castañeda, B., Simon, Y., Jacques, J. A., Hess, E., Choi, Y., Blin‐Wakkach, C., Mueller, C. G., Berdal, A., & Lézot, F. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22305 · Cited by 52

Vitamin D and regulation of gene expression.

Segaert, S., & Bouillon, R. (1998) · Current opinion in clinical nutrition and metabolic care · doi:10.1097/00075197-199807000-00006 · Cited by 57

Effects of polyethylene and TiAIV wear particles on expression of RANK, RANKL and OPG mRNA

Baumann, B., Rader, C., Seufert, J., Nöth, U., Rolf, O., Eulert, J., & Jakob, F. (2004) · Acta Orthopaedica Scandinavica · doi:10.1080/00016470410001222 · Cited by 59

Expression of parathyroid hormone‐related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor‐κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas

Kumamoto, H., & Ooya, K. (2003) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2004.00204.x · Cited by 51

Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis

Aoki, S., Honma, M., Kariya, Y., Nakamichi, Y., Ninomiya, T., Takahashi, N., Udagawa, N., & Suzuki, H. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.89 · Cited by 54

Osteoprotegerin and RANKL in alcoholic liver cirrhosis

Fábrega, E., Orive, A., García‐Suarez, C., García‐Unzueta, M., Antonio Amado, J., & Pons‐Romero, F. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01073.x · Cited by 48

Porphyromonas gingivalis-derived Lysine Gingipain Enhances Osteoclast Differentiation Induced by Tumor Necrosis Factor-α and Interleukin-1β but Suppresses That by Interleukin-17A

Akiyama, T., Miyamoto, Y., Yoshimura, K., Yamada, A., Takami, M., Suzawa, T., Hoshino, M., Imamura, T., Akiyama, C., Yasuhara, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520510 · Cited by 50

A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway

Raju, R., Balakrishnan, L., Nanjappa, V., Bhattacharjee, M., Getnet, D., Muthusamy, B., Thomas, J. K., Sharma, J. N., Rahiman, B. A., Gowda, H., et al. (2011) · Database · doi:10.1093/database/bar021 · Cited by 49

Anti-Inflammatory and Anti-Catabolic Effects of Creatine Supplementation: A Brief Review

Cordingley, D. M., Cornish, S. M., & Candow, D. G. (2022) · Nutrients · doi:10.3390/nu14030544 · Cited by 58

Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials

Wang, Y., Tran, K. K., Shen, H. Y., & Grainger, D. W. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.039 · Cited by 48

Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis

Bolon, B. N., Campagnuolo, G., & Feige, U. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8530-7 · Cited by 49

Gravitational and Space Biology

Landis, W. J. (2005) · Cited by 48

Osteoporosis in the elderly with chronic kidney disease

ERSOY, F. F. (2006) · International Urology and Nephrology · doi:10.1007/s11255-006-9109-2 · Cited by 47

Treatment of Myoblastic C2C12 Cells with BMP-2 Stimulates Vitamin D-induced Formation of Osteoclasts

Otsuka, E., Notoya, M., & Hagiwara, H. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-1071-0 · Cited by 49

RANKL:Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis

Rouster‐Stevens, K. A., Langman, C. B., Price, H. E., SESHADRI, R. M., Shore, R. M., Abbott, K., & Pachman, L. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22433 · Cited by 49

Osteoprotegerin (OPG) binds with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): Suppression of TRAIL-induced apoptosis in ameloblastomas

Sandra, F., Hendarmin, L. A., & Nakamura, S. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2005.09.009 · Cited by 47

Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients

Vezzani, G., Quartesan, S., Cancellara, P., Camporesi, E. M., Mangar, D., Bernasek, T. L., Dalvi, P. H., Yang, Z., Paoli, A., Rizzato, A., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1302440 · Cited by 48

Role of mechanical stress on the function of periodontal ligament cells

Pavasant, P., & Yongchaitrakul, T. (2011) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00374.x · Cited by 46

The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal models

Neumann, E., Gay, S., & Müller‐Ladner, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21361 · Cited by 45

The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1α,25-dihydroxyvitamin D3

Zhang, D., Yang, Y., Li, X. T., & Fu, M. (2003) · Archives of Oral Biology · doi:10.1016/s0003-9969(03)00201-2 · Cited by 47

Increased Levels of Osteoprotegerin in Hemodialysis Patients

Avberšek-Lužnik, I., Malešič, I., Rus, I., & Marc, J. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.177 · Cited by 47

Therapeutic targeting of osteoclast function and pathways

Broadhead, M. L., Clark, J. C. M., Dass, C. R., Choong, P., & Myers, D. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.546351 · Cited by 46

Osteoprotegerin in Human Milk: A Potential Role in the Regulation of Bone Metabolism and Immune Development

Vidal, K., BROEK, P. V. D., Lorget, F., & Donnet‐Hughes, A. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000127014.22068.15 · Cited by 46

Regulatory mechanisms of sclerostin expression during bone remodeling

Koide, M., & Kobayashi, Y. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0971-7 · Cited by 47

Multimerization of the Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis

Ikeda, T., Kasai, M., Suzuki, J., Kuroyama, H., Seki, S., Utsuyama, M., & Hirokawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304636200 · Cited by 48

Predictive, preventive, personalised and participatory periodontology: ‘the 5Ps age’ has already started

Cafiero, C., & Matarasso, S. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-16 · Cited by 54

The Genetics of Paget's Disease of the Bone

Leach, R. J., Singer, F. R., & Roodman, G. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7112 · Cited by 46

Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide ofTreponema denticola

Choi, B., Lee, H. J., Kang, J. H., Jeong, G. J., Min, C. K., & Yoo, Y. (2002) · Infection and Immunity · doi:10.1128/iai.71.1.226-233.2003 · Cited by 47

Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation

Kobayashi‐Sakamoto, M., Isogai, E., Hirose, K., & Chiba, I. (2008) · Microvascular Research · doi:10.1016/j.mvr.2008.06.004 · Cited by 45

Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice

Sgariglia, F., Candela, M. E., Huegel, J., Jacenko, O., Koyama, E., Yamaguchi, Y., Pacifici, M., & Enomoto‐Iwamoto, M. (2013) · Bone · doi:10.1016/j.bone.2013.08.012 · Cited by 45

RNA therapeutics targeting osteoclast-mediated excessive bone resorption

Wang, Y., & Grainger, D. W. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.002 · Cited by 45

RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible

Montonen, M., Li, T.-F., Lukinmaa, P.-L., Sakai, E., Hukkanen, M., Sukura, A., & Konttinen, Y. T. (2006) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2006.00454.x · Cited by 45

Receptor Activator for Nuclear Factor Kappab Ligand and Osteoprotegerin: Regulators of Bone Physiology and Immune Responses/Potential Therapeutic Agents and Biochemical Markers

Buckley, K. A., & Fraser, W. D. (2002) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456320203900602 · Cited by 45

Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro

Hasegawa, T., Kikuiri, T., Takeyama, S., Yoshimura, Y., Mitome, M., Oguchi, H., & Shirakawa, T. (2002) · Tissue and Cell · doi:10.1054/tice.2002.0223 · Cited by 45

NF-κB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells

Kobayashi‐Sakamoto, M., Hirose, K., Isogai, E., & Chiba, I. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.024 · Cited by 45

A novel molecular mechanism modulating osteoclast differentiation and function

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S.-I., Tsuda, E., Morinaga, T., Udagawa, N., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00121-0 · Cited by 264

Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin / Osteoclastogenesis-Inhibitory Factor

Shima, N., Yasuda, H., Nakagawa, N., Yamaguchi, K., Tsuda, E., Morinaga, T., Suda, T., & Higashio, K. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46869-7_43 · Cited by 1

Recent Advance in Osteoclastogenesis Inhibitory Factor.

Zhi, H. (2000) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS

16. Lack of antagonist activity of melanocyte-stimulating hormone (MSH) on the actions of IL-1 on human bone-derived osteoblast-like cells

Evans, D., Thavarajah, M., & Kanis, J. A. (1991) · Bone · doi:10.1016/8756-3282(91)90112-v

Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells

Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., & Yamada, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27091 · Cited by 299